Regenerex Pharma (RGPX) 10-Q 7 Feb 25 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2024	Feb. 07, 2025
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--03-31
Entity File Number	000-53230
Entity Registrant Name	REGENEREX PHARMA, INC.
Entity Central Index Key	0001357878
Entity Tax Identification Number	98-0479983
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5348 Vegas Drive #177
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89108
City Area Code	(877)
Local Phone Number	761-7479
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		278,465,910

BALANCE SHEETS (UNAUDITED)

BALANCE SHEETS (UNAUDITED) - USD ($)	Dec. 31, 2024	Mar. 31, 2024
Current Assets
Cash and equivalents	$ 338	$ 372
Prepaid expenses	650	2,540
Total Current Assets	988	2,912
Website, net of accumulated amortization of $30,600 and $29,272, as of December 31 and March 31, 2024,respectively		1,328
Furniture and computer equipment, net of accumulated depreciation of $2,900 and $1,600, as of December 31 and March 31, 2024,respectively	4,797	6,097
Right of use asset	641,075	756,343
Total Assets	646,860	766,680
Current Liabilities
Accounts payable	184,681	116,760
Related party advances	9,847	3,690
Accrued compensation	802,502	511,847
Other accrued liabilities	141,874	97,251
Current portion of notes payable	2,824,232	2,400,000
Current portion of leases liabilities	177,422	128,264
Total Current Liabilities	5,160,046	3,843,362
Notes payable, net of current portion		184,232
Lease liabilities, net of current portion	540,528	681,798
Total Liabilities	5,700,574	4,828,506
Commitments and Contingencies (Note 7)
Stockholders’ Deficit
Common stock: $0.001 par value; 675,000,000 shares authorized; 278,465,910 and 278,225,910 issued and outstanding as of December 31, 2024 and March 31, 2024, respectively	278,466	278,226
Additional paid-in capital	1,400,326	1,275,798
Accumulated deficit	(6,732,506)	(5,615,850)
Total Stockholders’ Deficit	(5,053,714)	(4,061,826)
Total Liabilities and Stockholders’ Deficit	646,860	766,680
Shareholder [Member]
Current Liabilities
Current portion of notes payable	611,226	475,050
Notes payable, net of current portion		119,114
Other Affiliates [Member]
Current Liabilities
Current portion of notes payable	$ 408,262	$ 110,500

BALANCE SHEETS (UNAUDITED) (Par

BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Dec. 31, 2024	Mar. 31, 2024
Statement of Financial Position [Abstract]
Finite-Lived Intangible Assets, Accumulated Amortization	$ 30,600	$ 29,272
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 2,900	$ 1,600
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	675,000,000	675,000,000
Common Stock, Shares, Issued	278,465,910	278,225,910
Common Stock, Shares, Outstanding	278,465,910	278,225,910

STATEMENTS OF OPERATIONS (UNAUD

STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Operating Expenses
General and administrative	$ 294,130	$ 239,384	$ 806,793	$ 785,481
Research and development	17,380		17,380	2,400,000
Total Operating Expenses	311,510	239,384	824,173	3,185,481
Operating Loss	(311,510)	(239,384)	(824,173)	(3,185,481)
Other Income (Expense)
Interest expense	(27,016)	(20,219)	(315,505)	(58,526)
Foreign currency gain (loss)	24,000	(4,373)	23,022	(6,993)
Total Other Income (Expense)	(3,016)	(24,592)	(292,483)	(65,519)
Net Loss	$ (314,526)	$ (263,976)	$ (1,116,656)	$ (3,251,000)
Basic and Diluted Loss per Common Share	$ 0	$ 0	$ 0	$ (0.01)
Weighted Average Number of Common Shares Outstanding	278,436,236	277,919,497	278,326,178	277,539,983

STATEMENTS OF CASH FLOWS (UNAUD

STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash Flows from Operating Activities:
Net loss	$ (1,116,656)	$ (3,251,000)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization	2,628	3,133
Stock-based compensation	74,768	154,634
Non-cash research and development expenses		2,400,000
Non-cash extension fee to Greenwich Resources	240,000
Amortization of ROU assets, net of liabilities	23,156	41,250
Foreign currency adjustments	(23,022)	6,993
Changes in operating assets and liabilities:
Prepaid expenses	1,890	(1,423)
Accounts payable	121,307	102,090
Accrued compensation	290,655	193,770
Other accrued liabilities	44,623	(42,560)
Net cash used in operating activities	(340,651)	(393,113)
Cash Flows from Investing Activities:
Purchase of furniture and computer equipment		(6,299)
Net cash used in investing activities		(6,299)
Cash Flows from Financing Activities:
Related party advances, net	6,157	4,557
Repayment of notes payable to related parties		(39,500)
Repayment of notes payable to shareholder		(10,000)
Proceeds from notes payable to shareholder		39,500
Proceeds from sale of common stock and warrants	50,000	343,250
Net cash provided by financing activities	340,617	406,133
Increase in cash and equivalents	(34)	6,721
Cash and cash equivalents, beginning of period	372	1,135
Cash and cash equivalents, end of period	338	7,856
Supplemental Cash Flow Information – Cash Paid For:
Income Taxes
Interest
Non-Cash Investing and Financing Activities:
Accrued interest converted into notes payable to shareholder	38,721	46,198
Accrued interest converted into notes payable to related parties	13,302	52,546
Operating leases, ROU asset and liabilities	52,203	953,535
Note payable issued for research and development		2,400,000
Note payable for interest expense	240,000
Affiliated Entity [Member]
Cash Flows from Financing Activities:
Repayment of notes payable to related parties	(284,460)	(105,000)
Proceeds from notes payable to shareholder	284,460	105,000
Other Affiliates [Member]
Cash Flows from Financing Activities:
Repayment of notes payable to related parties		(2,826)
Proceeds from notes payable to shareholder		$ 2,826

STATEMENTS OF STOCKHOLDERS' DEF

STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Mar. 31, 2023	$ 277,113	$ 671,963	$ (2,072,023)	$ (1,122,947)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2023	277,112,660
Shares and warrants sold for cash	343	342,907		343,250
Stock-based compensation	$ 460	$ 132,928		$ 133,388
Stock Issued During Period, Shares, Issued for Services				460,000
Net loss			(2,987,024)	$ (2,987,024)
Ending balance, value at Sep. 30, 2023	$ 277,916	1,147,798	(5,059,047)	(3,633,333)
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2023	277,915,910
Beginning balance, value at Mar. 31, 2023	$ 277,113	671,963	(2,072,023)	(1,122,947)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2023	277,112,660
Net loss				(3,251,000)
Ending balance, value at Dec. 31, 2023	$ 277,946	1,169,014	(5,323,023)	(3,876,063)
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2023	277,945,910
Beginning balance, value at Sep. 30, 2023	$ 277,916	1,147,798	(5,059,047)	$ (3,633,333)
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2023	277,915,910
Shares and warrants sold for cash				30,000
Stock-based compensation	$ 30	21,216		$ 21,246
Net loss			(263,976)	(263,976)
Ending balance, value at Dec. 31, 2023	$ 277,946	1,169,014	(5,323,023)	(3,876,063)
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2023	277,945,910
Beginning balance, value at Mar. 31, 2024	$ 278,226	$ 1,275,798	$ (5,615,850)	$ (4,061,826)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2024	278,225,910			278,225,910
Shares and warrants sold for cash	50	49,950		50,000
Stock-based compensation	$ 160	$ 56,635		$ 56,795
Stock Issued During Period, Shares, Issued for Services				160,000
Net loss			(802,130)	$ (802,130)
Ending balance, value at Sep. 30, 2024	$ 278,436	1,382,383	(6,417,980)	(4,757,161)
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2024	278,435,910
Beginning balance, value at Mar. 31, 2024	$ 278,226	1,275,798	(5,615,850)	$ (4,061,826)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2024	278,225,910			278,225,910
Net loss				$ (1,116,656)
Ending balance, value at Dec. 31, 2024	$ 278,466	1,400,326	(6,732,506)	$ (5,053,714)
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2024	278,465,910			278,465,910
Beginning balance, value at Sep. 30, 2024	$ 278,436	1,382,383	(6,417,980)	$ (4,757,161)
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2024	278,435,910
Stock-based compensation	$ 30	17,943		$ 17,973
Stock Issued During Period, Shares, Issued for Services				30,000
Net loss			(314,526)	$ (314,526)
Ending balance, value at Dec. 31, 2024	$ 278,466	$ 1,400,326	$ (6,732,506)	$ (5,053,714)
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2024	278,465,910			278,465,910

NATURE OF OPERATIONS

NATURE OF OPERATIONS	9 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1 – NATURE OF OPERATIONS Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005. On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15 th The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter the wound treatment market in the U.S. Risks and Uncertainties Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows. The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors. The wound care healing space is well suited for Home Care service providers that are funded by the US Government. Strategic planning and development will be performed internally by the Company.

BASIS OF PRESENTATION OF INTERI

BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended December 31, 2024, are not necessarily indicative of the results that may be expected for the year ending March 31, 2025. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2024, have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2024, included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2024, it had excess liabilities over assets of $5,053,714. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company requires significant cash to launch its business and reduce its payable. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government, State Medicaid Programs, International Health Care Programs, Veteran’s administration, Prison system, Home Health Care Providers, and other applicable Medicare reimbursement models. The Company will defer revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. Earnings per Share Earnings per share is reported in accordance with FASB ASC Topic 260 “ Earnings per Share During the nine months ended December 31, 2024, the Company excluded the outstanding stock warrants from its calculation of earnings per share, as the warrants would be anti-dilutive. As at December, 2024 and 2023, the Company had common shares warrants outstanding of 3,036,250 and 2,432,250, respectively. Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2024 and 2023 was $208 and $723 and $1,328 and $2,160, respectively. Furniture and Computer Equipment Furniture and computer equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years. Depreciation expense for the three and nine months ended December 31, 2024 and 2023 was $435 and $435 and $1,300 and $973, respectively. Significant betterments are capitalized while purchases under $500 are expensed as incurred. Right of Use Assets and Lease Liabilities The Company has active operating lease arrangements for office space, production equipment, and production facilities. The Company is required to make fixed minimum rent payments relating to its right to use the underlying leased asset. In accordance with the adoption of ASC 842, the Company recorded right-of-use assets and related lease liabilities for these leases as of December 2024. The Company’s lease agreements do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an incremental borrowing rate of 10% to discount each of its lease liabilities based on the remining lease term. Stock-Based Compensation The Company recognizes the cost of share-based payment awards on a straight-line attribution basis over the requisite employee service period and over the non-employee’s period of providing goods or services. Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise and the associated volatility. The Company estimates the fair value of options granted using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period of time the options are expected to be outstanding. Expected stock price volatility is based on the historical volatility of comparable public companies’ common stock for a period approximating the expected life, and the risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. The fair value of restricted stock awards is based on the fair value of the Company’s common stock on the date of the grant. Research and Development We incur research and development costs during the process of researching and developing additional technologies purchased and future manufacturing processes. Our research and development costs consist primarily of the purchase of additional intellectual property that we will use in the development of our planned product. We expense these costs as incurred until the resulting product has been completed, tested, and made ready for commercial use. Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Dec. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 5 – RELATED PARTY TRANSACTIONS The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and the former Secretary/Treasurer (see note 6). On June 10, 2023, the Company, has entered into an agreement with Woundcare Labs, LLC., a party related to the CEO and the former CFO of the Company, to lease a plant and to lease equipment in Tennessee (see note 8). Related Party Advances A former Chief Financial Officer (“CFO”) of the Company had advanced the Company monies for operating expenses; no amounts were advanced during the periods presented. The advances were due on demand, but no later than June 30, 2023. The related party advances began to accrue interest at ten (10) percent per annum on July 1, 2019. During the nine months ended December 31, 2023, this note was transferred to a relative of the former CFO and was renewed upon maturity in the principal amount of $131,687 plus interest accrued as at June 30, 2023 in the amount of $52,545. Interest expense was $13,881 and $3,285 during the nine-month periods ended December 31, 2024 and 2023, respectively. This transaction is no longer considered related party in nature, and thus is included in notes payable in the accompanying balance sheet. During the nine-month periods ended December 31, 2024 and 2023, the Company’s Chief Executive Officer (“CEO”) and the Company’s former Chief Financial Officer (“CFO”) advanced the Company monies for operating expenses in the net amount of $ and $ , respectively. The related party advances totaled $9,847 and $3,690 as of December 31, 2024 and March 31, 2024. Notes Payable to Related Parties During the nine-month periods ended December 31, 2024 and 2023, the Company’s CEO and former CFO advanced the Company monies for operating expenses in the amount of $284,460 and $105,000, respectively. Repayments during the nine-month periods ended December 31, 2024 and 2023 were $0 and $39,500, respectively. The notes are unsecured and accrue interest at ten (10) percent per annum. Repayment is due no later than six months after the date of issue and range from January 18, 2025 to June 30, 2025. During the nine-months ended December 31, 2024, seven notes with principal amount of $163,860 that came due during the period was reissued in the amount of $177,162 which included the principal amount plus accrued interest of $13,302. These notes are unsecured and bears interest at ten (10) percent per annum. Repayment is due no later than six months after the date of issue and range from March 5, 2025 to June 21, 2025. The related party notes payable totaled $408,262 and $110,500 as at December 31, 2024 and March 31, 2024. Interest expenses were $16,354 and $2,443 during the nine-month periods ended December 31, 2024 and 2023, respectively, which is included in other accrued liabilities at December 31, 2024 and March 31, 2024, respectively. Note Payable to Shareholder As at December 31, 2024 and March 31, 2024, the Company had various promissory notes with total outstanding principal balances of $611,226 and $594,164, respectively, due to a shareholder of the Company. These notes are unsecured, bear interest at % per annum, and have maturity dates ranging from to . During the nine-months ended December 31, 2024, twenty-three notes with principal amounts totaling approximately $193,900 ($262,264 Canadian Funds) that came due during the period were reissued in the approximate total principal amount $207,400 ($287,018 Canadian Funds) which included the principal amount plus approximate accrued interest of $13,500 ($24,754 Canadian Funds). During the nine-months ended December 31, 2024, an additional eight notes with principal amounts totaling $144,845 that came due during the period were reissued in the total principal amount of $163,899 which included the principal amount plus accrued interest of $19,054. These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due twelve (12) months after the date of issue. Interest expenses were $45,269 and $58,492 during the nine-month periods ended December 31, 2024 and 2023, respectively, which is included in other accrued liabilities at December 31, 2024 and March 31, 2024, respectively.

INTANGIBLE ASSETS AND INTELLECT

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	9 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY On November 15, 2021, the Company entered into an Related Party Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months. The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. On August 17, 2023, the Company entered into an Agreement to Purchase Technology Platforms in which the Company purchased certain intellectual property in exchange for a two million four hundred thousand dollars ($2,400,000) note payable. The intellectual property that was purchased requires further development prior to the product being finalized and produced so it has been expensed as research and development. The note payable was due within twelve (12) months of the date of the agreement and is included in current liabilities. As the Company did not raise a minimum of ten million dollars ($10,000,000) in sales within twelve (12) months of the agreement date, or a maximum of ten million dollars ($10,000,000) in investment, the seller extended the payment for a further period of twelve (12) months for a 10% payment of the outstanding balance which is included in current liabilities. The Technology Platforms include but are not limited to: A. Proteomic research platforms which include proprietary blends. B. Combination design Techniques C. Patent Pending Proprietary Blends D. Patent Pending Formulas E. Trademarks and all pending Trademarks F. 510K USA FDA, information, and Know-how for application G. All Clinical trials, (Right to use) H. CE mark (International) I. Regenerex Library formula incorporated in the Wound Healing Technology. J. Wound Healing Technology QBX K. Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark. Products: 1. Xcellderma over the counter product. 2. Accelerex, combination product as a drug device. 3. Accelerex in a tube.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 – COMMITMENTS AND CONTINGENCIES The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers. See Note 6 for discussion of the $10,000,000 in contingent consideration to be paid in connection with the November 15, 2021 Related Party Asset Purchase Agreement. Payments made to the Company’s CEO and former CFO in connection with the Asset Purchase Agreement are $0 and $43,500 as at December 31, 2024 and March 31, 2024. The outstanding liability of $22,988 and $15,488 as at December 31, 2024 and March 31, 2024 respectively is included in other accrued liabilities.

OPERATING LEASES

OPERATING LEASES	9 Months Ended
	Dec. 31, 2024
Operating Leases
OPERATING LEASES	NOTE 8 – OPERATING LEASES On April 1, 2023, the Company entered into an office lease agreement commencing in May 2023 which expires on April 30, 2028. Under this agreement, the monthly rental payments are $1,650 throughout the term of the lease. On September 6, 2024, the lease agreement was amended to expire November 1, 2024. The Company is required to pay for all utilities used on the premises and has paid a security deposit of $800 which was refunded August 30, 2024. As a result of the lease modification, the right of use assets and liabilities were remeasured as of the date of modification, resulting in the reduction in the ROU assets and liabilities of $59,919, with no material impact on the statement of operations. On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028. Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company’s procedures. Until October 1, 2024, the monthly rent was reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15 th On October 8, 2024, the Company entered into an office lease agreement commencing November 1, 2024 which expires on October 31, 2029. Under this agreement, the monthly rental payments are $1,100 throughout the term of the lease. Sewer and water utilities monthly payment of $50 is to be added to the monthly rental payments. During the three and nine-month periods ended December 31, 2024 and 2023 the operating lease cost was $54,501 and $55,720 and $166,205 and $137,171, respectively and is included in general and administrative expenses in the accompanying financial statements.

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	9 Months Ended
	Dec. 31, 2024
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 9 – STOCKHOLDERS’ DEFICIT The Company has authorized the issuance of 675,000,000 shares of common stock with a par value of $0.001 per share. During the nine months ended December, 2024 and 2023, the Company issued 190,000 and 490,000 shares, respectively, to board members and consultants for services rendered. Total stock-based compensation expense for the three and nine-month periods ended December 31, 2024 and 2023 was $5,400 and $5,400 and $34,200 and $88,200 respectively, in connection with these issuances based on the fair value of the stock on the respective grant dates. During the nine months ended December 31, 2024 and 2023, the Company issued 378,000 and 716,000 warrants to board members and consultants for services rendered with a total grant date fair value of $38,530 and $72,501, respectively, Total stock-based compensation expense of $40,568 and $66,434 was recorded in connection with these awards during the nine months ended December, 2024 and 2023, respectively. The warrants are fully vested and contain an exercise price of $0.33 per share and expire on dates ranging from July 1, 2029 to October 1, 2030. On December 5, 2024, the Company entered into an agreement to engage Brent Wilson, CPA as a consultant and to serve as the Chief Financial Officer. In addition to an hourly rate of compensation, Brent Wilson will be issued 60,000 warrants with an exercise price of $0.33 per share. The shares shall be earned on a prorated basis, calculated monthly from January 1, 2025 through January 1, 2026. The warrants shall be issued 30,000 in July 2025 and 30,000 in January 2026. The warrant fair values were estimated using a Black Scholes model with a 5-year expected term, risk-free interest rate ranging from 3.58% to 5.19%, a dividend yield of 0%, and an annualized standard deviation of stock price volatility of 80.0%. The risk-free interest rate assumptions for options granted is based upon observed interest rates on the United States government securities appropriate for the expected term of the equity awards. As of the date of this valuation, the Company's stock was not trading. The volatility was calculated based on comparable public companies. The Company will continue to monitor peer companies and other relevant factors used to measure expected volatility for future equipment award grants, until such time that the Company’s Common Stock has enough market history to use historical volatility. The dividend yield assumption for equity awards granted is based on Company’s history and expectation of dividend payouts. The Company has never declared or paid any cash dividends on its Common Stock, and the Company does not anticipate paying any cash dividends in the foreseeable future. The closing stock price of the Company’s common stock is not available as the Company’s stock is not trading. As a result, the Board of Directors and management determined the fair value of the common stock to be $0.18 per share based upon an allocation of the recent cash price paid for common stock and warrants during the nine months ended December 31, 2024. During the nine-month period ended December 31, 2024 and 2023, the Company issued 50,000 and 343,250 shares of common stock with a par value of $0.001 for the price of one ($1) dollar per share for a total of $50,000 and $343,250, respectively. One warrant was issued for each share purchased during the nine-month period ended December 31, 2024 for a total of 50,000 warrants. Five warrants were issued for each share purchased during the nine-month period ended December 31, 2023, for a total of 1,716,250 warrants. The warrants are exercisable at 0.20 cents and expire from March 2025 through August 2026. As of December 31, 2024, 3,036,250 warrants had been issued and vested. None of the warrants have been exercised.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS Subsequent to the nine-month period ended December 31, 2024, one additional note to a shareholder that was originally due in January 2025 with a principal amount of $1,081 was reissued in the principal amount of $1,135 which included the original principal amount of $1,081 plus interest accrued in the amount of $54. Repayment of the note is due July 7, 2025. Subsequent to the nine-month period ended December 31, 2024, nine additional notes to a shareholder that were originally due in January 2025 with a principal amount of approximately $97,800 ($134,640 Canadian Funds) were reissued in the principal amount of approximately $99,300 ($143,065 Canadian Funds) which included the original principal amount of approximately $97,800 ($134,640 Canadian Funds) plus interest accrued in the approximate amount of $1,500 ($8,425 Canadian Funds). Repayment of the note is due within six (6) months of the date of renewal. Subsequent to the nine-month period ended December 31, 2024, one additional note to a related party that was originally due in January 2025 with a principal amount of $56,500 was reissued in the principal amount of $59,325 which included the original principal amount of $56,500 plus interest accrued in the amount of $2,825. Repayment of the note is due July 8, 2025. On January 15, 2025, the Company signed a financial services agreement with J. Samuel Lee, JR to provide the services of Chief Operating Officer as a consultant. As compensation, J. Samuel Lee, JR will receive 5,000 common shares of stock in January 2025 and 10,000 shares of common stock each month thereafter. In January 2025, the Company acquired the shares of a private company Regenerex SDN BHD that was incorporated in Malaysia. Regenerex SDN BHD has no assets and currently has no operations. It was acquired for the purpose of opening a bank account and doing business in that country. The directors of Regenerex SDN BHD are the same as the current directors of Regenerex Pharma, Inc. In February 2025, consultants signed agreements receiving 10,000 common shares monthly as compensation.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government, State Medicaid Programs, International Health Care Programs, Veteran’s administration, Prison system, Home Health Care Providers, and other applicable Medicare reimbursement models. The Company will defer revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.
Earnings per Share	Earnings per Share Earnings per share is reported in accordance with FASB ASC Topic 260 “ Earnings per Share During the nine months ended December 31, 2024, the Company excluded the outstanding stock warrants from its calculation of earnings per share, as the warrants would be anti-dilutive. As at December, 2024 and 2023, the Company had common shares warrants outstanding of 3,036,250 and 2,432,250, respectively.
Website	Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2024 and 2023 was $208 and $723 and $1,328 and $2,160, respectively.
Furniture and Computer Equipment	Furniture and Computer Equipment Furniture and computer equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years. Depreciation expense for the three and nine months ended December 31, 2024 and 2023 was $435 and $435 and $1,300 and $973, respectively. Significant betterments are capitalized while purchases under $500 are expensed as incurred.
Right of Use Assets and Lease Liabilities	Right of Use Assets and Lease Liabilities The Company has active operating lease arrangements for office space, production equipment, and production facilities. The Company is required to make fixed minimum rent payments relating to its right to use the underlying leased asset. In accordance with the adoption of ASC 842, the Company recorded right-of-use assets and related lease liabilities for these leases as of December 2024. The Company’s lease agreements do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an incremental borrowing rate of 10% to discount each of its lease liabilities based on the remining lease term.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes the cost of share-based payment awards on a straight-line attribution basis over the requisite employee service period and over the non-employee’s period of providing goods or services. Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise and the associated volatility. The Company estimates the fair value of options granted using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period of time the options are expected to be outstanding. Expected stock price volatility is based on the historical volatility of comparable public companies’ common stock for a period approximating the expected life, and the risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. The fair value of restricted stock awards is based on the fair value of the Company’s common stock on the date of the grant.
Research and Development	Research and Development We incur research and development costs during the process of researching and developing additional technologies purchased and future manufacturing processes. Our research and development costs consist primarily of the purchase of additional intellectual property that we will use in the development of our planned product. We expense these costs as incurred until the resulting product has been completed, tested, and made ready for commercial use.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

NATURE OF OPERATIONS (Details N

NATURE OF OPERATIONS (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2024	Nov. 15, 2021
Entity Incorporation, Date of Incorporation	Nov. 18, 2005
Asset Acquisition, Contingent Consideration, Liability		$ 10,000,000
Purchase Intellectual Property [Member]
Shares, Issued		150,000,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Dec. 31, 2024	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Equity, Attributable to Parent	$ 5,053,714	$ 4,757,161	$ 4,061,826	$ 3,876,063	$ 3,633,333	$ 1,122,947

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Class of Warrant or Right, Outstanding	3,036,250	2,432,250	3,036,250	2,432,250
Finite-Lived Intangible Asset, Useful Life	3 years		3 years
Amortization of Intangible Assets	$ 208	$ 723	$ 1,328	$ 2,160
Other Depreciation and Amortization	$ 435	$ 435	$ 1,300	$ 973
Lessee, Finance Lease, Discount Rate	10%		10%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years		3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years		5 years

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Related Party Transaction [Line Items]
Related Party Transaction, Rate			10%
[custom:RelatedPartyAdvances-0]	$ 9,847		$ 9,847		$ 3,690
Interest Expense, Operating and Nonoperating	27,016	$ 20,219	315,505	$ 58,526
[custom:NotesPayableRelatedParties-0]	408,262		408,262
[custom:NotesPayableToRelatedPartiesNetOfCurrentPortion-0]					110,500
Interest Expense, Debt			16,354	2,443
Accrued Liabilities, Current	141,874		141,874		97,251
Aggregate Interest Expense [Member]
Related Party Transaction [Line Items]
Accrued Liabilities, Current	45,269	58,492	45,269	58,492
Twenty Three Notes [Member]
Related Party Transaction [Line Items]
Notes Payable	193,900		193,900
Long-Term Debt, Gross	207,400		207,400
Interest Payable, Current	13,500		13,500
Eight Notes [Member]
Related Party Transaction [Line Items]
Notes Payable	144,845		144,845
Long-Term Debt, Gross	163,899		163,899
Interest Payable, Current	19,054		$ 19,054
Debt Instrument, Maturity Date, Description			due twelve (12) months after the date of issue
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Notes and Loans Payable	131,687		$ 131,687
[custom:RelatedPartyAdvances-0]	52,545		52,545
Affiliates [Member]
Related Party Transaction [Line Items]
Interest Expense, Operating and Nonoperating			13,881	3,285
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
[custom:RelatedPartyAdvances-0]	6,157	4,557	6,157	4,557
Chief Executive Officer And Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Notes and Loans Payable	284,460	$ 105,000	284,460	105,000
Proceeds from (Repayments of) Notes Payable			$ 0	$ 39,500
Debt Instrument, Interest Rate During Period			10%
Debt Instrument, Maturity Date Range, Start			Jan. 18, 2025
Debt Instrument, Maturity Date Range, End			Jun. 30, 2025
Related Party [Member] | Reissued Notes 2 [Member]
Related Party Transaction [Line Items]
Debt Instrument, Interest Rate During Period			10%
Debt Instrument, Maturity Date Range, Start			Mar. 05, 2025
Debt Instrument, Maturity Date Range, End			Jun. 21, 2025
Notes Payable	163,860		$ 163,860
Long-Term Debt, Gross	177,162		177,162
Interest Payable, Current	13,302		13,302
Due To A Shareholder 1 [Member]
Related Party Transaction [Line Items]
Notes and Loans Payable	$ 611,226		$ 611,226		$ 594,164
Debt Instrument, Interest Rate During Period			10%
Debt Instrument, Maturity Date Range, Start			Jan. 02, 2025
Debt Instrument, Maturity Date Range, End			Jun. 30, 2025

INTANGIBLE ASSETS AND INTELLE_2

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)	1 Months Ended
	Nov. 15, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Business Combination, Contingent Consideration Arrangements, Description	up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024	Nov. 15, 2021
Assets Sold under Agreements to Repurchase [Line Items]
Asset Acquisition, Contingent Consideration, Liability						$ 10,000,000
General and Administrative Expense	$ 294,130	$ 239,384	$ 806,793	$ 785,481
Accrued Liabilities, Current	141,874		141,874		$ 97,251
Asset Purchase Agreement Liability [Member]
Assets Sold under Agreements to Repurchase [Line Items]
Accrued Liabilities, Current	$ 22,988		22,988		15,488
Chief Executive Officer And Chief Financial Officer [Member]
Assets Sold under Agreements to Repurchase [Line Items]
General and Administrative Expense			$ 0		$ 43,500

OPERATING LEASES (Details Narra

OPERATING LEASES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Lessee, Lease, Description [Line Items]
Operating Lease, Expense			$ 1,650
Prepaid Expense, Current	$ 650		$ 650		$ 2,540
Lessee, Operating Lease, Description			On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028.  Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company’s procedures.  Until October 1, 2024, the monthly rent was reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of  each June from June 2023 to June 2027.
Office Lease [Member] | Security Deposit [Member]
Lessee, Lease, Description [Line Items]
Prepaid Expense, Current	800		$ 800
Plant Facility [Member]
Lessee, Lease, Description [Line Items]
Capital Lease Obligations, Current	7,920		7,920
Plant Facility [Member] | Monthly Rental Payments [Member]
Lessee, Lease, Description [Line Items]
Operating Leases, Future Minimum Payments Due	18,000		18,000
Plant Lease [Member]
Lessee, Lease, Description [Line Items]
Operating Lease, Cost	$ 54,501	$ 55,720	$ 166,205	$ 137,171

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Jan. 31, 2026	Jul. 31, 2025	Mar. 31, 2024
Defined Benefit Plan Disclosure [Line Items]
Common Stock, Shares Authorized	675,000,000				675,000,000				675,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001				$ 0.001				$ 0.001
Stock Issued During Period, Shares, Issued for Services	30,000		160,000	460,000
Stock Issued During Period, Value, Issued for Services	$ 17,973	$ 21,246	$ 56,795	$ 133,388
Class of Warrant or Right, Outstanding	3,036,250	2,432,250			3,036,250	2,432,250
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term					5 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate					0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate					80%
Stock Issued During Period, Shares, New Issues		30,000	50,000	343,250
Warrants Issued For Stock Purchase [Member]
Defined Benefit Plan Disclosure [Line Items]
Class of Warrant or Right, Outstanding	50,000	1,716,250			50,000	1,716,250
Common Stock Issued For Purchase [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues					50,000	343,250
Stock Issued During Period, Value, New Issues					$ 50,000	$ 343,250
Common Stock Fair Value [Member]
Defined Benefit Plan Disclosure [Line Items]
Share Price	$ 0.18				$ 0.18
Range Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					3.58%
Range Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					5.19%
Board Members And Consultants [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, Issued for Services					190,000	490,000
Stock Issued During Period, Value, Issued for Services	$ 5,400	$ 5,400			$ 34,200	$ 88,200
Board Members And Consultants [Member] | Services Rendered [Member]
Defined Benefit Plan Disclosure [Line Items]
Class of Warrant or Right, Outstanding	378,000	716,000			378,000	716,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$ 38,530	$ 72,501			$ 38,530	$ 72,501
[custom:StockBasedCompensationUnrecognizedCompensationCost-0]	$ 40,568	$ 66,434			$ 40,568	$ 66,434
August 2026					Oct. 01, 2030
Board Members And Consultants [Member] | Services Rendered [Member] | Warrants [Member]
Defined Benefit Plan Disclosure [Line Items]
0.20	$ 0.33				$ 0.33
Chief Executive Officer [Member] | Services Rendered [Member]
Defined Benefit Plan Disclosure [Line Items]
August 2026					Jan. 01, 2026
Chief Executive Officer [Member] | Compensation [Member]
Defined Benefit Plan Disclosure [Line Items]
Class of Warrant or Right, Outstanding	60,000				60,000		30,000	30,000
Chief Executive Officer [Member] | Compensation [Member] | Warrants [Member]
Defined Benefit Plan Disclosure [Line Items]
0.20	$ 0.33				$ 0.33

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended
	Jan. 31, 2025	Feb. 28, 2025	Jan. 15, 2025	Dec. 31, 2024	Mar. 31, 2024
Subsequent Event [Line Items]
Common Stock, Shares, Issued				278,465,910	278,225,910
Subsequent Event [Member] | J Samuel Lee Jr [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued	10,000		5,000
Subsequent Event [Member] | Consultants [Member] | Monthly [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued		10,000
Subsequent Event [Member] | Reissued Notes 1 [Member]
Subsequent Event [Line Items]
Notes Payable	$ 1,081
Long-Term Debt, Gross	1,135
Debt Instrument, Issued, Principal	1,081
Interest Payable, Current	$ 54
Debt Instrument, Maturity Date	Jul. 07, 2025
Subsequent Event [Member] | Reissued Notes 2 [Member]
Subsequent Event [Line Items]
Notes Payable	$ 97,800
Long-Term Debt, Gross	99,300
Debt Instrument, Issued, Principal	97,800
Interest Payable, Current	1,500
Subsequent Event [Member] | Reissued Notes 3 [Member]
Subsequent Event [Line Items]
Notes Payable	56,500
Long-Term Debt, Gross	59,325
Debt Instrument, Issued, Principal	56,500
Interest Payable, Current	$ 2,825
Debt Instrument, Maturity Date	Jul. 08, 2025